

Supplementary Table 1. Glycemic parameters at baseline and 8 weeks after treatment

Variable	ATOMEGA (n=95)				Atorvastatin (n=96)				P for change between two groups
	Baseline, mg/dL (mean±SD)	Week 8, mg/dL (mean±SD)	Percent change (mean±SEM)	P for change between baseline and week 8	Baseline, mg/dL (mean±SD)	Week 8, mg/dL (mean±SD)	Percent change (mean±SEM)	P for change between baseline and week 8	
FPG (total)	141.9±53.2	145.7±45.9	8.4±3.3	0.535	133.9±37.9	134.9±35.7	4.1±2.7	0.651	0.288
DM	146.1±54.6	149.4±46.9	8.6±3.7	0.628	137.4±37.6	139.2±35.4	4.6±2.7	0.636	0.393
Non-DM	106.0±10.5	113.9±15.0	7.6±3.4	0.052	102.2±12.9	101.6±16.2	-0.3±3.5	0.965	0.124
HbA1c (total)	7.4±1.3	7.5±1.3	2.2±0.8	0.051	7.2±1.1	7.2±1.3	0.8±0.9	0.423	0.246
DM	7.6±1.2	7.7±1.2	2.2±0.9	0.064	7.4±1.1	7.4±1.2	0.9±1.0	0.414	0.346
Non-DM	5.6±0.4	5.7±0.5	2.2±1.3	0.159	5.7±0.4	5.7±0.3	-0.3±0.7	0.623	0.120

Data was measured in 191 subjects. The number of the subjects with DM was 85 in ATOMEGA group and 85 in atorvastatin group. The number of the subjects without DM was 10 in ATOMEGA group and 11 in atorvastatin group.

SD, standard deviation; SEM, standard error of the mean; FPG, fasting plasma glucose; DM, diabetes mellitus; HbA1c, hemoglobin A1c.